Topical methods and compositions for the treatment of eye diseases and conditions
The present invention relates to a new therapeutic approach for the treatment of eye diseases or conditions that allows for the delivery of corticosteroids to the eye's surface but does not cause any of the usual side effects associated with topical administration of corticosteroids. More specifically, the present invention provides methods of treatment involving the administration of a corticosteroid prodrug, such as dexamethasone palmitate, to the surface of the eye. Also provided are pharmaceutical compositions and kits for carrying out such methods of treatment.
1. A pharmaceutical composition comprising an effective amount of a corticosteroid prodrug selected from the group consisting of dexamethasone, physiologically acceptable salts thereof, esters thereof, or any combinations thereof and at least one pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier is a cationic emulsion comprising medium chain triglyceride and quaternary ammonium compounds, and wherein the pharmaceutical composition is formulated for topical administration to the surface of the eye, such that administration of the pharmaceutical composition to a subject's eye surface results in insignificant penetration of the corticosteroid prodrug or corticosteroid or both inside the eye.
2. The pharmaceutical composition according to claim 1 , wherein the corticosteroid prodrug comprises a lipophilic long chain ester of a dexamethasone, wherein said lipophilic long chain is selected from the group consisting of linear alkyls, branched alkyls, linear alkenyls, and branched alkenyls, wherein alkyls and alkenyls comprise 12, 14, 16, 18, or more carbon atoms.
3. The pharmaceutical composition according to claim 1 , wherein the corticosteroid prodrug is dexamethasone myristate, dexamethasone laurate or dexamethasone caprate.
4. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is formulated using an oily carrier.
5. The pharmaceutical composition according to claim 1 , wherein the corticosteroid prodrug is converted to dexamethasone at the surface of the eye by enzymatic cleavage.
6. The pharmaceutical composition according to claim 1 , wherein the pharmaceutically acceptable carrier or excipient is a member of the group consisting of antioxidant, viscosifying agent, preservative, pH adjusting agent, buffering agent, osmotic agent, chelating agent, penetration enhancing agent, and any combination thereof.
7. The pharmaceutical composition according to claim 1 further comprising at least one additional pharmaceutically active substance, preferably selected from the group consisting of an analgesic, an anesthetic, a haemostatic agent, an antimicrobial agent, an antibacterial agent, an antiviral agent, an antifungal agent, an antibiotic, an anti-inflammatory agent, an antioxidant, an antiseptic agent, an antihistamine agent, an antipruritic agent, an antipyretic agent, an immunostimulating agent, a dermatological agent, a anti-cancer agent, and any combination thereof.
8. The pharmaceutical composition of claim 7 , wherein the additional pharmaceutical active substance is a cyclosporine.
9. The pharmaceutical composition according to claim 1 , wherein the corticosteroid prodrug comprises a lipophilic long chain ester of dexamethasone, wherein said lipophilic long chain is selected from the group consisting of linear alkyls, branched alkyls, linear alkenyls, and branched alkenyls, wherein alkyls and alkenyls comprise 12, 14, 16, 18, or more carbon atoms.